14 January 2021
Reading time: 1 minutes

BarentsKrans advises Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics

BarentsKrans has advised Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics.

Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS (Central Nervous System) disorders.

“At Angelini Pharma, we are thrilled to sign this promising agreement and are enthusiastic about the commitment and work that our colleagues at Arvelle have put into the business during the last years. We share the same patient-centric culture and agility attitude” says Pierluigi Antonelli, CEO Angelini Pharma. “This transaction will propel us into a leading European player, well positioned to address the needs of patients with different Central Nervous System (CNS) disorders through an innovative portfolio, distinctive medical capabilities and extensive commercial presence, also via the opening of direct affiliates in France, UK, Nordics and Switzerland by 2022.”

Harry Rek, Thomas van Hövell tot Westervlier, Lisanne Vissers, Marleen van der Horst and Allard van Duijn were involved in this transaction.

For more information, please be referred to this statement.